A brick building on the corner of 8th Street and Gunnison Avenue in Grand Junction holds so many memories. Teenagers once ...

Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the body’s nerves. Immune cells ...

Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, ...

BTK Bank has successfully concluded a major bond issuance, raising 40 million dinars in a move that underscores the ...

Ascentage Pharma Group International has obtained IND approval from the FDA for its BTK-targeted protein degrader APG-3288. A phase I study will be conducted in patients with relapsed or refractory ...

A new cellular balance test can detect a hidden inflammation in the brain, helping physicians to spot multiple sclerosis ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

A new study has discovered a possible biomarker linked to multiple sclerosis disease progression that could help identify ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the co ...